MOTS-c

A mitochondrial-derived peptide studied mainly for metabolism in mice. Human data are observational only, and no completed human trial of giving it to people appears here.

The basics

Human protocol on record	None published
Animal or laboratory figures	1
Published records retrieved	17
Registered trials	9
Certificate of analysis	Published by the partner
Regulatory status	Research-grade material, no approved human use

1. The protocol on record

Hard disclaimer. Figures below are transcribed from a published study or an approved label exactly as the source states them. They record what researchers administered in a trial population, not instructions for any person, and none of it is adjusted to you. Most compounds here have no approved human use. Do not act on any of it without a licensed prescriber who knows your history.

Amounts and schedules, human record

No published human protocol exists for MOTS-c in the cited record. No amount, frequency or schedule can be given here without inventing it, and this page does not invent figures.

Animal and laboratory models (not human figures)

Phase or model	Amount	Frequency	Timing	Route	Duration	Source
Mouse immobilization-induced skeletal muscle atrophy model, MOTS-c-treated group	15 mg/kg	per day	not stated	injection	8 days	source

Half-life and why the schedule looks like that

No half-life, clearance or duration-of-action figure is stated anywhere in the cited record. The record does state one dosing frequency: 15 mg/kg per day by injection for 8 days, in a mouse model of immobilization-induced skeletal muscle atrophy (PMID: 38170165). That is an animal figure, not a human schedule. A phase 2 trial in adults with prediabetes and overweight or obesity is listed as recruiting, but its record states no amount, frequency, route or schedule (NCT07505745). No human dosing frequency is stated in the cited record.

Handling and storage

- Lyophilised storage: Not stated in the cited record. - Storage after reconstitution: Not stated in the cited record. - Temperature: Not stated in the cited record. - Light: Not stated in the cited record. - Stability duration: Not stated in the cited record.

These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.

Open the interactive builder for reconstitution maths and a calendar →

2. Safety and harm reduction

Reported adverse effects

Effect	How often reported	Population	Source
Exacerbation of the senescence-associated secretory phenotype (SASP): increased secretion of IL-6, IL-1β, IL-8, IL-10 and tumor necrosis factor α by senescent cells	frequency not stated	senescent cell model (in vitro)	PMID: 30058454

Cautions stated in the literature

Rigorous human safety data for unapproved peptides including MOTS-c are scarce, and there is potential for serious harm to patients; MOTS-c appears in the review's list of unapproved compounds marketed direct to patients outside regulatory oversight (PMID: 41966639).
No effective method of applying MOTS-c in the clinic has been developed (PMID: 36761202).
A naturally occurring K14Q MOTS-c variant has reduced CK2 binding and does not activate CK2; male carriers showed a higher risk of sarcopenia and type 2 diabetes in an age- and physical-activity-dependent manner, meaning genotype may alter response (PMID: 39559755).

Stop and get help

A severe or worsening reaction of any kind.
Signs of an allergic reaction: rash, itching, swelling of face or throat, trouble breathing, dizziness.
Signs of injection-site infection: spreading redness, warmth, swelling, pus, fever.
Any effect that is unexpected and persistent.

MOTS-c at Peptara Labs

Read the third-party certificate of analysis before anything else. Research-grade material, research use only.

Open the MOTS-c page